IP Verse

Kit Comprising Antibody Specifically Binding To Complement Factor B Protein And Antibody Specifically Binding To Carbohydrate Antigen 19-9 Protein For Diagnosing Pancreatic Cancer - EP3144676

The patent EP3144676 was granted to JW on Dec 11, 2019. The application was originally filed on Sep 3, 2014 under application number EP14892029A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3144676

JW
Application Number
EP14892029A
Filing Date
Sep 3, 2014
Status
Granted And Under Opposition
Nov 8, 2019
Grant Date
Dec 11, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DEHMEL & BETTENHAUSEN PATENTANWALTE PARTMBBSep 10, 2020RUCKERLWITHDRAWN

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTKR20130034505
INTERNATIONAL-SEARCH-REPORTKR20130116433
INTERNATIONAL-SEARCH-REPORTWO2012120288
OPPOSITIONKR20130116433
OPPOSITIONWO2004055519
OPPOSITIONWO2012120288
SEARCHWO2004055519

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- DATABASE WPI, 1, Derwent World Patents Index, (20000605) [Y] 6 * See the entire document. * [A] 1-5,7-
INTERNATIONAL-SEARCH-REPORT- LEE, MIN JUNG et al., "Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma", Journal of Proteome Research, (20140724), vol. 13, no. 11, pages 4878 - 4888, XP055236746 [PX] 1-7 * See the entire document. *
INTERNATIONAL-SEARCH-REPORT- PANG, WEI WEI et al., "Can the acute-phase reactant proteins be used as cancer biomarkers?", The International Journal of Biological Markers, (20100000), vol. 25, no. 1, pages 1 - 11, XP055236728 [A] 1-7 * See the entire document. *
OPPOSITION- CHU et al., "Identification and Screening of Individuals at Increased Risk for Pancreatic Cancer with Emphasis on Known Environmental and Genetic Factors and Hereditary Syndromes", J. Pancreas, (20100000), vol. 11, no. 3, pages 203 - 212, XP055767464-
OPPOSITION- DEL VILLANO et al., "Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9", Clin. Chem, (19830000), vol. 29, no. 3, pages 549 - 552, XP055767471-
OPPOSITION- FRY et al., "Molecular markers of pancreatic cancer: development and clinical relevance", Langenbecks Arch Surg, (20080000), vol. 393, pages 883 - 890, XP019657905
OPPOSITION- GOONETILLEKE et al., "Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer", Eur J Surg Oncol, (20060000), vol. 33, no. 3, pages 266 - 270, XP022005489
OPPOSITION- LEE et al., "Identification of Human Complement Factor B as a Novel Biomarker Candidate for Pancreatic Ductal Adenocarcinoma", J Proteome Res, (20140000), vol. 13, no. 11, pages 4878 - 4888, XP055236746
OPPOSITION- DUFFY et al., "Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report", Ann Oncol, (20100000), vol. 21, no. 3, pages 441 - 447, XP055767459
OPPOSITION- BLOOMSTON et al., "Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples", Cancer Res, (20060000), vol. 66, no. 5, pages 2592 - 2599, XP002484528
OPPOSITION- KOOPMAN et al., "Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9", Clin Cancer Res, (20060000), vol. 12, no. 2, pages 442 - 446, XP055767457
OPPOSITION- BOECK et al., "Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer", Oncology, (20060000), vol. 70, pages 255 - 264, XP055767454
OPPOSITION- PANG et al., "Can the acute-phase reactant proteins be used as cancer biomarkers?", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, (20100000), vol. 25, no. 1, pages 1 - 11, XP055236728
OPPOSITION- PORUK et al., "The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates", Curr Mol Med, (20130000), vol. 13, no. 3, pages 340 - 351, XP055767448
OPPOSITION- BALLEHANINNA et al., "The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal", J. Gastrointestinal Oncol, (20120000), vol. 3, no. 2, pages 105 - 119, XP055767468
OPPOSITION- MISEK et al., "Early Detection and Biomarkers in Pancreatic Cancer", J. Nat Comprehensive Cancer Network, (20070000), vol. 5, no. 10, pages 1034 - 1041, XP055767465
SEARCH- K. E. Poruk ET AL, "The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates", Current Molecular Medicine, (20130301), pages 340 - 351, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419808/pdf/nihms-683610.pdf, (20170818), XP055399678 [X] 13 * the whole document * [A] 1-12,14-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents